TRL V6 Biomarker Prediction of Antipsychotic Weight Gain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to predict which patients will experience treatment emergent weight gain when administered certain pharmaceutical agents, such as atypical antipsychotics and PPAR-gamma agonists, prior to actual weight gain observation.
Innovation Solution
The use of large triglyceride-rich lipoprotein particles of the V6 subclass (TRL V6) as a biomarker to determine an individual's risk of treatment emergent weight gain by measuring TRL V6 concentration changes in response to pharmaceutical agents, employing methods that include administering doses and fat loads while monitoring TRL V6 responses using NMR spectrometry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmaceutical agents such as atypical antipsychotics are administered to treat psychological disorders, then therapeutic effectiveness is improved, but treatment emergent weight gain occurs as a harmful side effect in subpopulations of patients
Solution Approach 1:
The patent applies preliminary action by measuring TRL V6 concentration before initiating pharmaceutical therapy to predict which patients are at risk for treatment emergent weight gain. This prescreening approach allows clinicians to identify susceptible individuals beforehand and adjust treatment plans proactively, rather than waiting for weight gain to occur after treatment begins.
Solution Approach 2:
The patent implements feedback by using TRL V6 concentration measurements as a biomarker to provide information about individual patient susceptibility to weight gain. This feedback mechanism enables clinicians to monitor predicted risk and make informed decisions about treatment selection or co-treatments to mitigate potential weight gain while maintaining therapeutic effectiveness.
2Loss of information
If TRL V6 concentration is measured to predict treatment emergent weight gain risk, then ability to prescreen patients is improved, but complexity of measurement and analysis increases
Solution Approach 1:
The patent applies taking out by isolating and measuring specifically the TRL V6 subclass of triglyceride-rich lipoprotein particles from patient biosamples. By focusing on this particular biomarker subset rather than performing comprehensive lipid panel analysis, the method extracts the critical predictive information needed while simplifying the measurement process compared to analyzing all lipoprotein fractions.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Methods for using TRL V6 as a biomarker for the risk of weight gain associated with treatment of a patient with a pharmaceutical agent, as for example, olanzapine.